A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; TAK 117 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 11 May 2017 Planned End Date changed from 1 Dec 2018 to 31 Aug 2018.
- 11 May 2017 Planned primary completion date changed from 1 Dec 2018 to 31 Aug 2018.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.